Ogawa Chie, Tsuchiya Ken, Maeda Kunimi, Nitta Kosaku
Contrib Nephrol. 2018;195:62-73. doi: 10.1159/000486936. Epub 2018 May 7.
Normal iron metabolism is essential for effective hemoglobin (Hb) production in the management of renal anemia. Considering that studies regarding the optimal Hb levels predated the creation of the iron management indices found in the treatment guidelines for hemodialysis (HD) patients, an increase in the Hb levels caused by intravenous iron supplementation has been used as an iron management index. However, no consideration was given to iron metabolism or the long-term safety of intravenous iron supplementation. Although iron is a vital trace element in humans, it can also be toxic, and its metabolism is carefully controlled, with several factors affecting it. Considering that the details regarding the mechanisms underlying iron metabolism have been elucidated recently, a study regarding iron management that is safe and considers iron metabolism status effective for Hb production in patients with renal anemia is warranted. This study presents information regarding iron metabolism in patients on HD, the factors that influence iron metabolism in such patients, and the problems with existing treatment guidelines in Japan, apart from discussing the optimal iron levels and optimal Hb production indices.
正常的铁代谢对于肾性贫血管理中有效生成血红蛋白(Hb)至关重要。鉴于有关最佳Hb水平的研究早于血液透析(HD)患者治疗指南中发现的铁管理指标的制定,静脉补铁导致的Hb水平升高已被用作铁管理指标。然而,并未考虑铁代谢或静脉补铁的长期安全性。尽管铁是人体必需的微量元素,但它也可能有毒,其代谢受到严格控制,有多种因素会对其产生影响。鉴于最近已阐明铁代谢潜在机制的详细情况,有必要开展一项关于铁管理的研究,该研究要安全且考虑到铁代谢状态对肾性贫血患者Hb生成的有效性。本研究除了讨论最佳铁水平和最佳Hb生成指标外,还介绍了HD患者的铁代谢信息、影响此类患者铁代谢的因素以及日本现有治疗指南存在的问题。